Top Analytics Companies in Boston, MA (150)

Strong Revenue Growth: Revenue is expanding with consecutive year-over-year increases in the first half of 2026 and management raising the full‑year outlook. The quarter ended June 30, 2026 also closed at nearly a $1.5 billion annualized run rate.

Profitability: Margins and cash generation are improving, with recent quarters showing positive non‑GAAP operating income and strong free cash flow. Materials also highlight operating discipline alongside growth.

Market Expansion: International revenue is outpacing the Americas, supported by new regional hubs such as Dublin and Singapore. Rising adoption of additional channels (e.g., SMS/WhatsApp) and larger‑account wins indicate a broader addressable market.

Strategic Partnerships: Partnerships with Quest Analytics (June 16, 2025) and collaborations such as with the American College of Surgeons, alongside a growing Aggregate user conference in 2025–2026, align with commercial momentum. Announced marketplace additions and ecosystem integrations further point to an expanding partner network.

Investor Backing & Capital Strength: Nordic Capital became the majority owner in July 2025 to support a “next phase of growth,” building on a $125 million financing from Vista Credit Partners in 2023. These moves signal access to capital to scale the platform and accelerate expansion.

Product Line Growth: A next‑gen lakehouse‑based data platform launched in February 2024 and subsequent 2025–2026 AI/interoperability capabilities—building on the CareJourney acquisition—indicate continued product expansion. New solutions such as Network Modeler and Contract IQ are cited as part of this cadence.

Resilient & Sustainable Growth: Growth is described as measured and predictable, with signals such as modest headcount expansion, sustained operating scale, and continued momentum rather than volatility.

Innovation-Driven Growth: Recent major releases across IRIS/IRIS for Health/Health Connect and new AI-focused offerings indicate ongoing R&D velocity that broadens capabilities and use cases.

Strong Market Position & Advantage: Repeated industry accolades for Shared Care Records/HIE and regional acute EHRs in 2026 point to durable competitive standing in core healthcare markets.

Strong Revenue Growth: Revenue expanded rapidly, with FY2025 up 83% to about $1.27B and Q1/Q2 2026 up 36% and 22% year over year, respectively. Management also raised 2026 revenue guidance to approximately $1.595–$1.605B.

Diversified Revenue Streams: Both Diagnostics and Data & Applications are expanding, with Diagnostics up 34.7% in Q1 and 20% in Q2 2026 and Insights/data licensing up 36% in Q2 alongside about $200M in new licenses. Rising oncology test volumes (28–31% YoY) and accelerating MRD tests (~4,700 in Q4 2025 to ~9,000 in Q2 2026) reinforce multiple growth engines.

Profitability: The company achieved its first GAAP-profitable quarter in Q2 2026 (net income about $5.6M; Adjusted EBITDA ~$8.0M). Guidance points to further improvement in 2026, indicating progress toward sustained profitability.

Market Expansion: The merger with Accolite in 2024, global rebrand in 2025, and the 2026 Cartesian acquisition broadened footprint across North America, Europe, and India. Leadership appointments to run the India practice indicate continued investment in global delivery capacity.

Innovation-Driven Growth: The Cartesian deal was positioned to accelerate enterprise AI capabilities, and joining Anthropic’s Claude Partner Network signals an AI-led services push. Feedback suggests these moves deepen data and analytics strengths rather than retrenchment.

Strategic Partnerships: Recent partner accolades such as Acquia’s 2024 North America Partner of the Year and broader ecosystem momentum point to healthy demand and platform depth. Alliances highlighted across AI and digital experience stacks support go-to-market expansion.

Market Expansion: Headcount and footprint are described as rising to more than 15,000 employees across 40-plus offices, alongside concrete new sites in Hyderabad and a completed Chicago buildout—signals of geographic and capacity expansion. These moves indicate confidence in demand across key delivery hubs.

Innovation-Driven Growth: A dedicated Platforms & Products unit, the ZAIDYN portfolio, and AI-agent initiatives point to sustained investment in productized, AI-enabled offerings. Capability-deepening acquisitions (Digital Additive in 2024 and Torrent Consulting in 2025) further strengthen CRM and multi‑cloud life‑sciences solutions.

Strategic Partnerships: An expanded Salesforce collaboration around Agentforce and recognition as Databricks 2025 Life Sciences Partner of the Year suggest momentum in data/AI ecosystems. These alliances position the firm to capture spend where CRM, data, and AI converge in healthcare and life sciences.

Profitability: Earnings and underwriting margins improved materially, with a full‑year 2025 combined ratio of 88.4% and year‑to‑date 87.3% in the first half of 2026 alongside higher net income. First‑half 2026 net income reached $4.686B versus $2.870B a year earlier, reflecting stronger underwriting and lower catastrophe losses.

Investor Backing & Capital Strength: Total equity increased to $44.1B by June 30, 2026, and core operating companies were upgraded to A+ by S&P on July 21, 2026. These markers indicate a fortified balance sheet and capacity to support selective expansion.

Resilient & Sustainable Growth: Deliberate portfolio pruning and disciplined underwriting (e.g., sale of Western European operations and other exits) reduced reported premiums while aiming to raise returns and lower volatility. The approach is characterized as “growing better” rather than “growing bigger,” prioritizing margin quality over volume.

Strong Market Position & Advantage: Placement as a Leader in Gartner’s 2024–2025 Magic Quadrant for Digital Experience Platforms and continued industry recognition indicate durable competitive standing. Ongoing Engage events and partner programs align with sustained enterprise adoption.

Innovation-Driven Growth: Active product expansion—such as the 2026 launches of Acquia AI and major Acquia Source updates, plus prior acquisitions like Monsido and Widen—shows continued investment in the platform. These moves broaden the DXP footprint across AI, DAM/PIM, and governance.

Customer Loyalty & Retention: Company retrospectives for 2022–2023 cite record renewal rates alongside multi‑year revenue increases. This points to a stable installed base that supports resilience through market cycles.

Strong Hiring & Retention: Hiring momentum, explicit “rapid growth” language on the careers page, and ongoing requisitions across Woburn/Boston, Arlington, Dayton, Melbourne, and San Diego point to expanding teams and stable retention. LinkedIn and careers postings indicate an active build-out across engineering and related functions.

Innovation-Driven Growth: Recent U.S. Navy awards, continued DARPA work through at least early 2026, and progress on multi‑phase programs (e.g., AIR and other DARPA initiatives) indicate expansion fueled by advanced R&D in AI/ML, sensing, cyber/EW, and mission software. Follow‑on options and modifications suggest programs are maturing rather than winding down.

Market Expansion: A five‑site U.S. footprint and active recruiting across these locations reflect scaled operations beyond a single hub. Participation on large DoD IDIQ vehicles and industry engagement (e.g., a CVPR 2026 workshop sponsorship) point to a widening market presence.

Investor Backing & Capital Strength: Recent capital raises include a $56.1M Series C in July 2024 and additional growth financing in March 2026 to expand product, sales, and customer success. These transactions point to strong investor support and resources to scale.

Product Line Growth: New and enhanced offerings such as the Group Health Risk Management Life Cycle (Sept 2025) and workers’ comp tools like ClaimVector and a 2026 triage solution indicate active product development. This expansion supports broader use cases across underwriting and claims.

Strong Revenue Growth: Company communications highlight double‑digit year‑over‑year growth since founding and well over 100% growth exiting 2022, with a later 50% YoY increase in platform volume. These signals suggest ongoing commercial momentum.

Strategic Partnerships: The acquisition by Model N positions Kalderos’s 340B and gross-to-net capabilities inside a larger life-sciences revenue platform, implying broader distribution and customer access. Integration of the Truzo claims-level visibility into Model N’s suite signals strategic value and scale-up potential.

Strong Revenue Growth: Company materials state revenue more than doubled two years in a row leading into 2023, alongside expanding customers and team. These signals point to strong pre-acquisition traction that can be leveraged under Model N.

Market Expansion: 340B drug purchases reached roughly $66.3B in 2023, indicating a large and expanding market the combined offering serves. This category tailwind supports ongoing demand for discount-management and gross-to-net solutions.

Investor Backing & Capital Strength: Funding milestones include a $71M Series C in February 2022 and total disclosed capital of about $114.5M, with backers such as Accel, Insight Partners, and Tiger Global. This capital base supports multi‑year scaling while the company continues executing without a newly announced post‑2022 round.

Innovation-Driven Growth: Product expansion since 2024 centers on AI-focused capabilities such as measuring the impact of AI coding tools, the AI Impact Dashboard (2024), and a smarter Jellyfish Assistant (March 2026). Partnerships (e.g., Augment Code) and ongoing research outputs (e.g., the 2026 State of Engineering Management) indicate an active roadmap aligned to emerging demand.

Strong Market Position & Advantage: Recognition includes placement as a Leader in Gartner’s inaugural 2026 Magic Quadrant for Developer Productivity Insight Platforms and sustained Leader status on G2’s Software Development Analytics Tools grid through 2026. Case studies with well-known brands and broader availability via AWS Marketplace (since 2023) reinforce category presence.

Strong Revenue Growth: Trade coverage indicates sustained double‑digit growth across 2024–2025 and substantial managed media spend. Recent high‑profile AOR wins and early‑2026 new‑business momentum reinforce the trajectory.

Strong Market Position & Advantage: Industry honors (e.g., Independent Agency of the Year) and a blue‑chip client roster signal competitive strength among independent, tech‑forward media/marketing agencies. Consistent recognition across multiple years points to durable standing rather than a one‑off result.

Market Expansion: New offices in Mexico City and Toronto, alongside acquisitions in retail media and influencer marketing, extend geographic reach and capabilities. Prior deals in CTV/OTT and the U.K./EU further support scaled indie positioning.

Customer Loyalty & Retention: Customer stickiness appears strong, supported by consistently high retention and an expanding base of global clients and users. The recurring subscription model is reinforced by retention remaining above the mid-90s level alongside continued footprint growth.

Resilient & Sustainable Growth: Revenue and earnings show a long pattern of steady increases across fiscal years and quarters, with guidance pointing to continued mid-single-digit expansion. Growth is characterized as durable rather than rapid, consistent with a mature, subscription-heavy business.

Future-Ready Strategy: Ongoing investment in AI and platform modernization signals a strategy aimed at sustaining competitiveness and workflow relevance over time. Leadership roles focused on AI and technology are positioned to accelerate these initiatives and embed next-generation capabilities into core products.

Strong Market Position & Advantage: GE HealthCare is positioned as a top-tier global medical technology player with leadership across diagnostic imaging, ultrasound, and pharmaceutical diagnostics, supported by a very large installed base and operations in over 160 countries. Scale and portfolio breadth across major modalities and care settings are repeatedly presented as durable advantages that support recurring service, upgrades, and consumables/software revenue.

Innovation-Driven Growth: R&D investment exceeding $1B annually and an active pipeline of many products in imaging, digital health, and in vitro diagnostics indicate a sustained innovation engine. The emphasis on AI-enabled devices and new product introductions (e.g., photon-counting CT and other launches) is framed as a multi-year driver that should increase contribution to revenue over time.

Resilient & Sustainable Growth: Orders and backlog signals (book-to-bill above 1.0, growing orders, and a reported record backlog) suggest demand is keeping pace with shipments and provides forward visibility. Guidance for continued low-single-digit organic growth alongside expectations for EPS growth and meaningful free cash flow points to steady, defensible expansion rather than cyclical contraction.